Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Merck
Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: August 15, 2022

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Brevibloc Double Strength In Plastic Container, and when can generic versions of Brevibloc Double Strength In Plastic Container launch?

Brevibloc Double Strength In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Brevibloc Double Strength In Plastic Container

A generic version of BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10th, 2004.

  Try it Free

Drug patent expirations by year for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
Recent Clinical Trials for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zagazig UniversityPhase 2
Cristália Produtos Químicos Farmacêuticos Ltda.Phase 4
University Hospital Bispebjerg and FrederiksbergPhase 4

See all BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER clinical trials

Pharmacology for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
Anatomical Therapeutic Chemical (ATC) Classes for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

US Patents and Regulatory Information for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 See Plans and Pricing See Plans and Pricing
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 See Plans and Pricing See Plans and Pricing
Baxter Hlthcare BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-005 Jan 27, 2003 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

See the table below for patents covering BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER around the world.

Country Patent Number Title Estimated Expiration
Slovakia 12782002 Formulácia esmololu (Esmolol formulation) See Plans and Pricing
Slovenia 1368019 See Plans and Pricing
Czech Republic 20023825 See Plans and Pricing
Hungary 0204520 See Plans and Pricing
World Intellectual Property Organization (WIPO) 8201869 See Plans and Pricing
Japan 2013151572 ESMOLOL FORMULATION See Plans and Pricing
Japan 5778384 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.